APA (7th ed.) Citation

G, L., M, L., A, A., S, B., A, G., P, D., . . . DC, Z. (2024). Immunotherapy after progression to double immunotherapy: Pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition. Frontiers in oncology, 14, 1420879. https://doi.org/10.3389/fonc.2024.1420879

Chicago Style (17th ed.) Citation

G, Lyrarakis, Liontos M, Anastasopoulou A, Bouros S, Gkoufa A, Diamantopoulos P, Gogas H, and Ziogas DC. "Immunotherapy After Progression to Double Immunotherapy: Pembrolizumab and Lenvatinib Versus Conventional Chemotherapy for Patients with Metastatic Melanoma After Failure of PD-1/CTLA-4 Inhibition." Frontiers in Oncology 14 (2024): 1420879. https://doi.org/10.3389/fonc.2024.1420879.

MLA (9th ed.) Citation

G, Lyrarakis, et al. "Immunotherapy After Progression to Double Immunotherapy: Pembrolizumab and Lenvatinib Versus Conventional Chemotherapy for Patients with Metastatic Melanoma After Failure of PD-1/CTLA-4 Inhibition." Frontiers in Oncology, vol. 14, 2024, p. 1420879, https://doi.org/10.3389/fonc.2024.1420879.